Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study
Open accessAbstract
Background: Whether vedolizumab may be effective as a treatment for primary sclerosing cholangitis [PSC] in patients with inflammatory bowel disease [IBD] remains controversial. Methods: We performed a retrospective observational study of consecutive patients with IBD and PSC, treated with vedolizumab for at least 30 weeks in 22 centres of GETAID from January 2015 to June 2016. The outcomes included a decrease in the serum alkaline phosphatase [ALP] concentration of at least 50% from baseline to Week 30 or 54, a change in any serum liver enzymes concentrations, and an assessment of the efficacy and safety of vedolizumab in IBD. Results: Among 75 patients with active IBD and PSC treated with vedolizumab, 21 patients discontinued vedolizumab before Week 30 [due to lack of efficacy in 19 and malignancy in two patients]. In the remaining 54 patients, a decrease in the serum ALP concentration of at least 50% from baseline to Weeks 30 and 54 was observed in four [7%] and four [11%] patients, respectively. No significant change was observed in serum liver enzyme concentrations at week 30 or 54. After a median follow-up period of 19.4 [14.0–29.9] months, nine cases of digestive neoplasia [colorectal neoplasia in seven and cholangiocarcinoma in two] were reported. Conclusions: In patients with IBD and PSC, vedolizumab did not improve serum liver enzyme concentrations at week 30 or 54. Nine cases of digestive cancer occurred during the follow-up period, confirming the need for a tight surveillance programme in this population.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Vedolizumab has a favourable safety profile and a moderate effect on IBD in PSC-IBD.
“Similar results have been reported for vedolizumab, the monoclonal antibody against integrin a4b7, with a favourable safety profile and a moderate effect on the IBD.[178][179][180]”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [178]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P. J., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A. D., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,910 · see citing works
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Harvey, R. F., & Bradshaw, J. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92767-1 · Cited by 2,974 · see citing works
Primary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868 · see citing works
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Colombel, J., Sands, B. E., Rutgeerts, P. J., Sandborn, W. J., Danese, S., D’Haens, G., Panaccione, R., Loftus, E. V., Sankoh, S., Fox, I. H., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311079 · Cited by 805 · see citing works
Boonstra, K., Weersma, R. K., van Erpecum, K. J., Rauws, E. A., Spanier, B. W. M., Poen, A. C., van Nieuwkerk, K. M., Drenth, J. P., Witteman, B. J., Tuynman, H. A., et al. (2013) · Hepatology · doi:10.1002/hep.26565 · Cited by 725 · see citing works
Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W., Dubé, R., Cohen, A., Steinhart, A. H., Landau, S. B., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042982 · Cited by 691 · see citing works
Primary sclerosing cholangitis
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D., & Adams, D. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60096-3 · Cited by 599 · see citing works
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598 · see citing works
Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis
Burak, K. W., Angulo, P., Pasha, T. M., Egan, K. M., Petz, J., & Lindor, K. D. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04067.x · Cited by 554 · see citing works
Primary Sclerosing Cholangitis
Lazaridis, K. N., & LaRusso, N. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1506330 · Cited by 528 · see citing works
Primary Sclerosing Cholangitis
(2007) · Gastroenterology Nursing · doi:10.1097/01.sga.0000267930.44372.16 · Cited by 382 · see citing works
Eksteen, B., Grant, A. J., Miles, A., Curbishley, S. M., Lalor, P. F., Hübscher, S. G., Briskin, M., Salmon, M., & Adams, D. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041035 · Cited by 360 · see citing works
Grant, A. J., Lalor, P. F., Hübscher, S. G., Briskin, M., & Adams, D. (2001) · Hepatology · doi:10.1053/jhep.2001.24231 · Cited by 297 · see citing works
Eaton, J. E., Silveira, M. G., Pardi, D. S., Sinakos, E., Kowdley, K. V., Luketic, V. A., Harrison, E. M., McCashland, T. M., Befeler, A. S., Harnois, D. M., et al. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.156 · Cited by 267 · see citing works
Grant, A. J., Lalor, P. F., Salmi, M., Jalkanen, S., & Adams, D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07374-9 · Cited by 255 · see citing works
Schreiber, S., Dignass, A. U., Peyrin‐Biroulet, L., Hather, G., Demuth, D., Mosli, M. H., Curtis, R. I., Khalid, J. M., & Loftus, E. V. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1480-0 · Cited by 175 · see citing works
Self-citationEksteen, B., Mora, J. R., Shepherd, E. L., Henderson, N. C., Lee–Turner, L., Villablanca, E. J., Curbishley, S. M., Aspinall, A. I., von Andrian, U. H., & Adams, D. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.046 · Cited by 132 · see citing works
Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease
Bye, W. A., Jairath, V., & Travis, S. P. L. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14075 · Cited by 117 · see citing works
Torres, J., de Chambrun, G. P., Itzkowitz, S. H., Sachar, D. B., & Colombel, J. F. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04753.x · Cited by 116 · see citing works
Expression of the mucosal vascular addressin, MAdCAM‐1, in inflammatory liver disease
Hillan, K. J., Hagler, K. E., MacSween, R. N. M., Ryan, A. M., Renz, M. E., Chiu, H. H., Ferrier, R. K., Bird, G. L. A., Dhillon, A. P., Ferrell, L. D., et al. (1999) · Liver International · doi:10.1111/j.1478-3231.1999.tb00084.x · Cited by 98 · see citing works
Christensen, B., Micic, D., Gibson, P. R., Yarur, A., Bellaguarda, E., Corsello, P., Gaetano, J. N., Kinnucan, J., Rao, V. L., Reddy, S., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14525 · Cited by 91 · see citing works
Luthra, P., Peyrin‐Biroulet, L., & Ford, A. C. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13215 · Cited by 82 · see citing works
Self-citationTse, C. S., Loftus, E. V., Raffals, L. E., Gossard, A. A., & Lightner, A. L. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14829 · Cited by 76 · see citing works
Screening for Malignancy in Primary Sclerosing Cholangitis (PSC)
Khaderi, S. A., & Sussman, N. (2015) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0438-0 · Cited by 45 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419 · see citing works
Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis
Hedin, C. R. H., Sado, G., Ndegwa, N., Lytvyak, E., Mason, A., Montano-Loza, A., Gerussi, A., Saffioti, F., Thorburn, D., Nilsson, E., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.02.014 · Cited by 52 · see citing works
Immunobiology of primary sclerosing cholangitis
Cornillet, M., Geanon, D., Bergquist, A., & Björkström, N. K. (2025) · Hepatology · doi:10.1097/hep.0000000000001080 · Cited by 20 · see citing works
- Authors
- Caron, B., Peyrin-Biroulet, L., Pariente, B., Bouhnik, Y., Seksik, P., Bouguen, G., Caillo, L., Laharie, D., Carbonnel, F., Altwegg, R., Reenaers, C., Serrero, M., Trang-Poisson, C., Nancey, S., Filippi, J., Abitbol, V., Savoye, G., Vuitton, L., Viennot, S., Fumery, M., Reymond, M., Bronowicki, J.-P., Reimund, J.-M., & Amiot, A.
- Affiliations
- Department of Gastroenterology, Hôpitaux Universitaires de Strasbourg [Hôpital de Hautepierre] and INSERM U1113 IRFAC, Université de Strasbourg [Faculté de Médecine], Strasbourg, France
- INSERM U954 and Department of Gastroenterology, Université de Lorraine, Nancy, France
- Université de Lille (FR)
- Hôpital Beaujon (FR)
- Inserm (FR)
- Hôpital Pontchaillou (FR)
- Centre Hospitalier Universitaire de Nîmes (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Université Paris-Sud (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Department of Gastroenterology, Liege University Hospital, Liege, Belgium
- Hôpital Nord, Centre d’investigation clinique Marseille Nord, Université Méditerranée, Marseille, France
- Department of Gastroenterology, Institut des Maladies de l’appareil Digestif [IMAD], University Hospital of Nantes, Nantes University, Nantes, France
- Department of Gastroenterology, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Pierre-Benite, France
- Department of Gastroenterology and Clinical Nutrition, Nice University Hospital, University of Nice Sophia-Antipolis, Nice, France
- Department of Gastroenterology, Cochin Hospital, University Paris 5 Descartes, Paris, France
- Institute for Research and Innovation in Biomedicine (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Department of Gastroenterology, Caen University Hospital, Caen, France
- Department of Gastroenterology, Amiens University Hospital, Amiens, France
- Université Clermont Auvergne (FR)
- Department of Gastroenterology, Henri Mondor Hospital, APHP, EC2M3-EA7375, Paris Est-Créteil Val de Marne University, Creteil, France
- ORCID
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05-06
- Volume
- 13
- Issue
- 10
- Pages
- 1239-1247
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- OpenAlex
- W2944756700
- Cited by
- 60
- References
- 24
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 12 · 2023: 10 · 2022: 8 · 2021: 7 · 2020: 5 · 2019: 4
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Crohn s and Colitis (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- ORBi (University of Liège) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- vedolizumab, primary sclerosing cholangitis
- MeSH terms
- Adolescent, Adult, Female, Gastrointestinal Agents, Humans, Male, Retrospective Studies, Cholangitis, Sclerosing, Inflammatory Bowel Diseases, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
